Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Brooke Benner"'
Autor:
Dionisia Quiroga DO, PhD, Robert Wesolowski MD, Sara Zelinskas BS, Ashley Pinette MD, Brooke Benner PhD, Emily Schwarz BS, Himanshu Savardekar BS, Courtney Johnson DO, Andrew Stiff MD, PhD, Lianbo Yu PhD, Erin Macrae MD, Maryam Lustberg MD, MPH, Ewa Mrozek MD, Bhuvaneswari Ramaswamy MD, William E. Carson MD
Publikováno v:
Cancer Control, Vol 31 (2024)
Objectives CpG ODN is a Toll-like receptor 9 agonist with immunotherapeutic potential for many cancer types, including aggressive breast cancers. There is strong interest in utilizing CpG ODN as an adjuvant to improve clinical efficacy of current tre
Externí odkaz:
https://doaj.org/article/c4a04ac8a9714a0fa31cf6f588fbd325
Autor:
Benjamin Krämer, Ansel P. Nalin, Feiyang Ma, Sarah Eickhoff, Philipp Lutz, Sonia Leonardelli, Felix Goeser, Claudia Finnemann, Gudrun Hack, Jan Raabe, Michael ToVinh, Sarah Ahmad, Christoph Hoffmeister, Kim M. Kaiser, Steffen Manekeller, Vittorio Branchi, Tobias Bald, Michael Hölzel, Robert Hüneburg, Hans Dieter Nischalke, Alexander Semaan, Bettina Langhans, Dominik J. Kaczmarek, Brooke Benner, Matthew R. Lordo, Jesse Kowalski, Adam Gerhardt, Jörg Timm, Marieta Toma, Raphael Mohr, Andreas Türler, Arthur Charpentier, Tobias van Bremen, Georg Feldmann, Arne Sattler, Katja Kotsch, Ali T. Abdallah, Christian P. Strassburg, Ulrich Spengler, William E. Carson, III, Bethany L. Mundy-Bosse, Matteo Pellegrini, Timothy E. O’Sullivan, Aharon G. Freud, Jacob Nattermann
Publikováno v:
Cell Reports, Vol 42, Iss 1, Pp 111937- (2023)
Summary: Group 1 innate lymphoid cells (ILCs) comprise a heterogeneous family of cytotoxic natural killer (NK) cells and ILC1s. We identify a population of “liver-type” ILC1s with transcriptional, phenotypic, and functional features distinct from
Externí odkaz:
https://doaj.org/article/0084e5451ed64fc0b420c8bfd7ffa888
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/6faf4dd040b946bc96549c749523dc71
Autor:
Robert Wesolowski, Andrew Stiff, Dionisia Quiroga, Christopher McQuinn, Zaibo Li, Hiroaki Nitta, Himanshu Savardekar, Brooke Benner, Bhuvaneswari Ramaswamy, Maryam Lustberg, Rachel M. Layman, Erin Macrae, Mahmoud Kassem, Nicole Williams, Sagar Sardesai, Jeffrey VanDeusen, Daniel Stover, Mathew Cherian, Thomas A. Mace, Lianbo Yu, Megan Duggan, William E. Carson
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-12 (2020)
Abstract Background While combinations of immune checkpoint (ICP) inhibitors and neo-adjuvant chemotherapy (NAC) have begun testing in patients with breast cancer (BC), the effects of chemotherapy on ICP expression in circulating T cells and within t
Externí odkaz:
https://doaj.org/article/70fdc2b010ae46fe8b7001ba65aea064
Autor:
Steven H. Sun, Brooke Benner, Himanshu Savardekar, Gabriella Lapurga, Logan Good, David Abood, Erin Nagle, Megan Duggan, Andrew Stiff, Mallory J. DiVincenzo, Lorena P. Suarez-Kelly, Amanda Campbell, Lianbo Yu, Robert Wesolowski, Harrison Howard, Hiral Shah, Kari Kendra, William E. Carson
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
IntroductionMyeloid-derived suppressor cells (MDSC) are a subset of immature myeloid cells that inhibit anti-tumor immunity and contribute to immune therapy resistance. MDSC populations were measured in melanoma patients receiving immune checkpoint i
Externí odkaz:
https://doaj.org/article/4a25a5c8cb994612b586c2751a095616
Autor:
Brooke Benner, William E. Carson
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-3 (2021)
Abstract Bruton’s tyrosine kinase (BTK) inhibitors, drugs utilized in cancer, are being repurposed for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) (COVID-19). Recently, BTK inhibitors acalabrutinib and ibrutinib have been found to
Externí odkaz:
https://doaj.org/article/aa9a3bf513de44ba8a9a66b7e41746be
Autor:
Brooke Benner, Luke Scarberry, Lorena P. Suarez-Kelly, Megan C. Duggan, Amanda R. Campbell, Emily Smith, Gabriella Lapurga, Kallie Jiang, Jonathan P. Butchar, Susheela Tridandapani, John Harrison Howard, Robert A. Baiocchi, Thomas A. Mace, William E. Carson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-14 (2019)
Abstract Background Tumor-associated macrophages (TAM) are expanded and exhibit tumor-promoting properties within the tumor microenvironment. Current methods to study TAM have not been replicated across cancer types and often do not include exogenous
Externí odkaz:
https://doaj.org/article/407995ec4f2d45019d23e2fcc67ec322
Autor:
Brooke Benner, Terence M Williams, Fouad Choueiry, Molly Torok, Kriti Agrawal, Anna Deems, Alice Hinton, Jami Shaffer, Bradley W Blaser, Anne M Noonan, Darwin L Conwell, Phil A Hart, Zobeida Cruz-Monserrate, Xue-Feng Bai, William E Carson III
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background A significant challenge to overcome in pancreatic ductal adenocarcinoma (PDAC) is the profound systemic immunosuppression that renders this disease non-responsive to immunotherapy. Our supporting data provide evidence that CD200, a regulat
Externí odkaz:
https://doaj.org/article/375dc23cd67940fa8b94d32e521b9303
Autor:
Brooke Benner, Luke Scarberry, Andrew Stiff, Megan C. Duggan, Logan Good, Gabriella Lapurga, Jonathan P. Butchar, Susheela Tridandapani, William E. Carson
Publikováno v:
OncoImmunology, Vol 8, Iss 11 (2019)
An inflammatory microenvironment has been shown to play an important role in the growth and metastasis of tumors. The NLRP3 inflammasome is a multi-protein complex of the innate immune system that is responsible for the production of the potent infla
Externí odkaz:
https://doaj.org/article/e4d23b2b1b9548adac3f9c4cdeb09aaf
Autor:
Dwight H. Owen, Brooke Benner, Lai Wei, Vineeth Sukrithan, Ashima Goyal, Ye Zhou, Carly Pilcher, Sheryl-Ann Suffren, Gwen Christenson, Nancy Curtis, Megan Jukich, Emily Schwarz, Himanshu Savardekar, Ruthann Norman, Sarah Ferguson, Barbara Kleiber, Robert Wesolowski, William E. Carson, Gregory A. Otterson, Claire F. Verschraegen, Manisha H. Shah, Bhavana Konda
Publikováno v:
Clinical Cancer Research. 29:731-741
Purpose:Treatment options are limited in patients with metastatic neuroendocrine neoplasms (NEN). We present the results for a phase II trial of combination nivolumab and temozolomide in patients with advanced NEN along with results of immune changes